Volume 2, Issue 1 (Multidisciplinary Cancer Investigation 2018)
Multidiscip Cancer Investig 2018, 2(1): 26-32 |
Back to browse issues page
1- Department of Industrial Engineering, Malek Ashtar University of Technology, Tehran, Iran , atashgar@iust.ac.ir
2- Department of Industrial Engineering, Malek Ashtar University of Technology, Tehran, Iran
3- Department of Radiotherapy, Isfahan University of Medical Science, Tehran,
4- Iran University of Medical Sciences, Tehran, Iran
2- Department of Industrial Engineering, Malek Ashtar University of Technology, Tehran, Iran
3- Department of Radiotherapy, Isfahan University of Medical Science, Tehran,
4- Iran University of Medical Sciences, Tehran, Iran
Abstract: (10426 Views)
Introduction: There is a lack of information on the extent of dependency between chronic diseases and the survival rate of breast cancer. Until date, none of the models proposed has determined the impact of chronic diseases on breast cancer survival. This study, therefore, aimed to investigate the impacts of chronic diseases such as diabetes, blood pressure, and endocrine disorders on the survival of breast cancer patients through a comprehensive research.
Methods: All (n = 1822) breast cancer patients treated in the three hospitals of Tehran from 2007 through mid–2016 were included in this study. A comprehensive study was conducted by focusing on the chronic disease data of the studied patients. The parametric and semi-parametric approaches, as well as non-parametric Kaplan-Meier analysis, were performed. This research proposes two models for analyzing breast cancer survival. A comparative analysis of the models was performed based on the Akaike criterion.
Results: Chronic diseases have been found to affect the survival of breast cancer patients. This research considered 436 individuals, among the patients with chronic diseases including hypertension, diabetes, hypo- and hyperthyroidism, and heart problems at the frequencies of 12.38%, 11.69%, 8.71%, and 8.02%, respectively. This study indicated that the 5-year survival of breast cancer patients with chronic diseases was 72% and that it was 82% for other breast cancer patients. The statistical analysis and the two proposed models revealed that chronic diseases significantly affect the survival of the
study patients.
Conclusions: This comprehensive research evidence a significant difference in the survival rate of breast cancer patients with and without chronic diseases. The statistical analysis of the data indicated that chronic diseases can significantly affect the survival probability in breast cancer. Heart problems and the combination of chronic diseases have a major influence on the survival rate of breast cancer patients as compared to other cases.
Select article type: Case Report and Series |
Subject:
Supportive and Palliative Care
Received: 2017/09/2 | Accepted: 2017/01/1 | ePublished: 2017/12/12
Received: 2017/09/2 | Accepted: 2017/01/1 | ePublished: 2017/12/12
References
1. Nguyen L, Brunicardi FC, Dibardino DJ, Scott BG, Awad SS, Bush RL, et al. Education of the modern surgical resident: novel approaches to learning in the era of the 80-hour workweek. World J Surg. 2006;30(6):1120-7. [DOI]
2. Lv M, Li B, Li Y, Mao X, Yao F, Jin F. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China. Asian Pac J Cancer Prev. 2011;12(9):2411-7. [PubMed]
3. Abadi A, Yavari P, Dehghani-Arani M, Alavi-Majd H, Ghasemi E, Amanpour F, et al. Cox models survival analvsis based on breast cancer treatments. Iran J Cancer Prev. 2014;7(3):124-9. [PubMed]
4. Rajaeifard AA, Talei A, Baneshi M. Survival analysis models for breast cancer patients in Shiraz, 1993-2002.
5. Yaghmaei S, Bani Hashemi G, Ghorbani R. Survival rate following treatment of primary breast cancer in Semnan, Iran (1991-2002). koomesh. 2008; 9 (2) :111-116
6. Bakhtiyari A, Haj Ahmadi M. year assessment of breast Cancer at Rajaii Hospital, Babolsar (1991-1996). The Iranian Journal of Obstetrics, Gynecology and Infertility.2006;9(1):47-51.
7. Sarkar K, Chowdhury R, Dasgupta A. Analysis of Survival Data: Challenges and Algorithm-Based Model Selection. J Clin Diagn Res. 2017;11(6):LC14-LC20. [DOI] [PubMed]
8. Davila-Arias C, Ocon O, Fernandez MF, Arrebola JP, Sanchez MJ, Aneiros J, et al. [Disease-free survival related factors in breast cancer]. Med Clin (Barc). 2014;143(7):293-9. [DOI] [PubMed]
9. Moghadami Fard Z, Gohari MR. Survival analysis of pa-tients with breast cancer using the Aalen›s additive hazard model. Journal of North Khorasan University of Medical Sciences. 2012; 15;3(5):171-9.
10. Moghadami Fard Z, Abolghasemi J, Asadi Lari M, Mohammadi M, Gohari MR, Salehi M. Factors affecting metastasis of breast cancer using frailty model. Majallah-i Danishgah-i Ulum-i Pizishki-i Arak. 2012;15(8):85–94.
11. Gohari MR, Khodabakhshi R, Shahidi J, Fard ZM, Foadzi H, Soleimani F et al. The impact of multiple recurrences in disease-free survival of breast cancer: an extended Cox model. Tumori. 2012;98(4):428–33. [PubMed]
12. Davila-Arias C, Ocon O, Fernandez MF, Arrebola JP, Sanchez MJ, Aneiros J, et al. [Disease-free survival related factors in breast cancer]. Med Clin (Barc). 2014;143(7):293-9. [DOI] [PubMed]
13. MokhtariHesari P. Moghadami Fard Z, khodabakhshi R, Gohari MR. Identification Prognostic factors for disease-free survival in breast Cancer patients. Journal of North Khorasan University of Medical Sciences. 2013;5(4):821–30.
14. Fardmal J, Mafi M, Sadighi-Pashaki A, Karami M, Roshanaei GH. Factors Affecting Survival in Breast Cancer Patients Referred to the Darol Aitam-e Mahdieh Center. Journal of Zanjan University of Medical Sciences. 2014;22:105–15.
15. Ghorbani N, Yazdani Cherati J, Anvari K, Ghorbani N. Factors Affecting Recurrence in Breast Cancer Using Cox Model. Majallah-i Danishgah-i Ulum-i Pizishki-i Mazandaran. 2015;25(132):32–9.
16. Atashgar K, Molana SH, Biglarian A, Sheikhaliyan A. Analysis of Survival Data of Patient with Breast Cancer Using Cox Regression Model. Indian J Surg. 2016;24(1):62–76. [PubMed]
17. Simsek F. Five Year Survival Analysis of Patients with Clinical Stages I and IIA Breast Cancer who Received Initial Treatment at North Carolina Hospitals. North Carolina Public Department of Health & Human services. 2000; 123: 1–10.
18. Vahdaninia M, Montazeri A. Breast cancer in Iran: a survival analysis. Asian Pac J Cancer Prev. 2004;5(2):223–5. PMID:15244529.
19. Warwick J, Taba L, Vitak B, Duffy S.W. Time-Dependent Effects on Survival in Breast Carcinoma: Results of 20 Years of Follow-Up from the Swedish Two-County Study American Cancer Society. 2004; 100 (7): 1331–1336.
20. Takahashi H, Watanabe K, Takahashi M, Taguchi K, Sasaki F, Todo S. The impact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer. Breast Cancer. 2005;12(3):196–202. [DOI] [PubMed]
21. Jerez JM, Franco L, Alba E, Llombart-Cussac A, Lluch A, Ribelles N et al. Improvement of breast cancer relapse pre-diction in high risk intervals using artificial neural networks. Breast Cancer Res Treat. 2005;94(3):265–72. [DOI] [PubMed]
22. Kurt Omurlu I, Ozdamar K, Tokatli F. Comparison of Bayesian survival analysis and Cox regression analysis in simulated and breast cancer data sets. Expert Syst Appl. 2009;36(8):11341–6. [DOI]
23. Kurt Omurlu I, Ture M, Tokatli F. The comparisons of random survival forests and Cox regression analysis with simulation and an application related to breast cancer. Expert Syst Appl. 2009;36(4):8582–8. [DOI]
24. Rezaianzadeh A, Peacock J, Reidpath D, Talei A, Hosseini SV, Mehrabani D. Survival analysis of 1148 women diagnosed with breast cancer in Southern Iran. BMC Cancer. 2009 Jun;9(168):168. [DOI] [PubMed]
25. Abadi A, Saadat S, Yavari P, Bajdik C, Jalili P. Comparison of Aalen’s additive and Cox proportional hazards models for breast cancer survival: analysis of population- based data from British Columbia, Canada. Asian Pac J Cancer Prev. 2011; 12(11):3113–6. [PubMed]
26. Alfonso AG, de Oca NA. Application of hazard models for patients with breast cancer in Cuba. Int J Clin Exp Med. 2011;4(2):148–56. [PubMed]
27. Colzani E, Liljegren A, Johansson AL, Adolfsson J, Hellborg H, Hall PF et al. Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol. 2011;29(30):4014–21. [DOI] [PubMed]
28. Ivanauskienė R, Gedminaitė J, Juozaitytė E, Vanagas G, Simoliūnienė R, Padaiga Z. Survival of women with breast cancer in Kaunas Region, Lithuania. Medicina (Kaunas). 2012;48(5):272–6. [PubMed]
29. Fouladi N, Amani F, Harghi AS, Nayebyazdi N. Five year survival of women with breast cancer in Ardabil, north-west of Iran. Asian Pac J Cancer Prev. 2011;12(7):1799–801. [PubMed]
30. Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN et al. Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis. Oncologist. 2011;16 (2):155–64. [DOI] [PubMed]
31. Faradmal J, Talebi A, Rezaianzadeh A, Mahjub H. Survival analysis of breast cancer patients using Cox and frailty models. J Res Health Sci. 2012 ;12(2):127–30. [PubMed]
32. Movahedi M, Haghighat S, Khayamzadeh M, Moradi A, Ghanbari-Motlagh A, Mirzaei H et al. Survival rate of breast cancer based on geographical variation in iran, a national study. Iran Red Crescent Med J. 2012;14(12):798–804. [DOI] [PubMed]
33. Abadi A, Amanpour F, Bajdik C, Yavari P. Breast Cancer Survival Analysis: Applying the Generalized Gamma Distribution under Different Conditions of the Proportional Hazards and Accelerated Failure Time Assumptions. Int J Prev Med. 2012 ;3(9):644–51. [PubMed]
34. Balabram D, Turra CM, Gobbi H. Survival of patients with operable breast cancer (Stages I-III) at a Brazilian public hospital—a closer look into cause-specific mortality. BMC Cancer. 2013 Sep;13(434):434. [DOI] [PubMed]
35. Bilal E, Dutkowski J, Guinney J, Jang IS, Logsdon BA, Pandey G et al. Improving breast cancer survival analysis through competition-based multidimensional modeling. PLOS Comput Biol. 2013;9(5):e1003047. [DOI] [PubMed]
36. Abadi A, Yavari P, Dehghani-Arani M, Alavi-Majd H, Ghasemi E, Amanpour F et al. Cox models survival analysis based on breast cancer treatments. Iran J Cancer Prev. 2014;7(3):124–9. [PubMed]
37. Faradmal J, Soltanian AR, Roshanaei G, Khodabakhshi R, Kasaeian A. Comparison of the performance of log-logistic regression and artificial neural networks for predicting breast cancer relapse. Asian Pac J Cancer Prev. 2014;15(14):5883–8. [DOI] [PubMed]
38. Vallinayagam V, Prathap S, Venkatesan P. Parametric Regression Models in the Analysis of Breast Cancer Surviv-al Data. International Journal of Science and Technology. 2014;3(3):163–7.
39. Fallahzadeh H, Momayyezi M, Akhundzardeini R, Zarezardeini S. Five year survival of women with breast cancer in Yazd. Asian Pac J Cancer Prev. 2014;15(16):6597–601. [DOI] [PubMed]
40. Mohammed U. Comparison Of Cox, Weibull And Gompertz Regression Models In Survival Analysis Using Breast Cancer Data (Doctoral Dissertation).
41. Baulies S, Belin L, Mallon P, Senechal C, Pierga JY, Cottu P et al. Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy. Br J Cancer. 2015;113 (1):30–6. [DOI] [PubMed]
42. Cetin K, Christiansen CF, Svaerke C, Jacobsen JB, Sorensen HT. Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval. BMJ Open. 2015;5(4):e007702. [DOI] [PubMed]
43. Shering SG, Zbar AP, Moriarty M, McDermott EW, O’Hig-gins NJ, Smyth PP. Thyroid disorders and breast cancer. Eur J Cancer Prev. 1996;5(6):504–6. [PubMed]
44. Rasmusson B, Feldt-Rasmussen U, Hegedüs L, Perrild H, Bech K, Høier-Madsen M. Thyroid function in patients with breast cancer. Eur J Cancer Clin Oncol. 1987;23(5):553–6.https://doi.org/10.1016/0277-5379(87)90319-1 [PubMed]
45. Maruchi N, Annegers JF, Kurland LT. Hashimoto’s thyroiditis and breast cancer. Mayo Clin Proc. 1976;51 (5):263–5. [PubMed]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |